PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those ...

Continuous anticoagulation may effectively reduce the incidence of thromboembolic events in patients with orthopedic trauma, ...

In a modeling analysis, initiating direct acting or nonvitamin K oral anticoagulants (DOAC/NOAC) in patients with device-detected subclinical atrial fibrillation (AF) provided a net gain of ...

Recognizing that D-dimer levels generally increase with advancing age, however, the age-adjusted D-dimer test is ...

SAN FRANCISCO, CA—Oral anticoagulation following transcatheter aortic valve replacement fails to lower the incidence of new subclinical cerebral lesions identified on imaging when compared with dual ...

A Win Ratio analysis confirmed the primary result of the NOAH—AFNET 6 trial and did not find an advantage of anticoagulation with edoxaban over no anticoagulation in patients with device-detected ...

Enzalutamide is an oral androgen receptor antagonist widely used to treat metastatic prostate cancer. Patients who are candidates for enzalutamide therapy are also at risk for the development of ...

LOS ANGELES, CA—To balance risks of hemorrhage and recurrent ischemic events, researchers continue to try to refine the optimal timing for initiation of oral anticoagulation after stroke in patients ...

Please provide your email address to receive an email when new articles are posted on . Rivaroxaban did not lower the composite outcome of stroke, systemic embolism and new covert embolism stroke vs.